Active replication — ongoing trial, registry, or meta-analysis.
Recent follow-up analyses of EMILIA are confirming the original effect size in real-world data.
TL;DR · AI-generated
T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al. · New England Journal of Medicine · 2012
· openalex W2159967578 · s2 c1be35f9
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0737
Recent follow-up analyses of EXTEND-IA are confirming the original effect size in real-world data.
0.0809
Recent follow-up analyses of ESCAPE are confirming the original effect size in real-world data.
0.0914
Recent follow-up analyses of EMPEROR-Reduced are confirming the original effect size in real-world data.
0.0948
Recent follow-up analyses of MEMBRANE are confirming the original effect size in real-world data.
0.0964
Recent follow-up analyses of ORBITA are confirming the original effect size in real-world data.
0.0991
Recent follow-up analyses of EARLYSTIM are confirming the original effect size in real-world data.